Literature DB >> 10749739

Adenoviral E3-14.7K protein in LPS-induced lung inflammation.

K S Harrod1, A D Mounday, J A Whitsett.   

Abstract

The adenoviral E3-14.7K protein is a cytoplasmic protein synthesized after adenoviral infection. To assess the contribution of E3-14. 7K-sensitive pathways in the modulation of inflammation by the respiratory epithelium, inflammatory responses to intratracheal lipopolysaccharide (LPS) and tumor necrosis factor (TNF)-alpha were assessed in transgenic mice bearing the adenoviral E3-14.7K gene under the direction of the surfactant protein (SP) C promoter. When E3-14.7K transgenic mice were administered LPS intratracheally, lung inflammation as indicated by macrophage and neutrophil accumulation in bronchoalveolar lavage fluid was decreased compared with wild-type control mice. Lung inflammation and epithelial cell injury were decreased in E3-14.7K mice 24 and 48 h after LPS administration. Intracellular staining for surfactant proprotein (proSP) B, proSP-C, and SP-B was decreased and extracellular staining was markedly increased in wild-type mice after LPS administration, consistent with LPS-induced lung injury. In contrast, intense intracellular staining of proSP-B, proSP-C, and SP-B persisted in type II cells of E3-14.7K mice, whereas extracellular staining of proSP-B and proSP-C was absent. Inhibitory effects of intratracheal LPS on SP-C mRNA were ameliorated by expression of the E3-14.7K gene. Similar to the response to LPS, lung inflammation after intratracheal administration of TNF-alpha was decreased in E3-14.7K transgenic mice. Levels of TNF-alpha after LPS administration were similar in wild-type and E3-14.7K-bearing mice. Cell-selective expression of E3-14.7K in the respiratory epithelium inhibited LPS- and TNF-alpha-mediated lung inflammation, demonstrating the critical role of respiratory epithelial cells in LPS- and TNF-alpha-induced lung inflammation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749739     DOI: 10.1152/ajplung.2000.278.4.L631

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  7 in total

1.  Cavidine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via NF-κB Signaling Pathway in vivo and in vitro.

Authors:  Xiaofeng Niu; Fang Liu; Weifeng Li; Wenbing Zhi; Hailin Zhang; Xiumei Wang; Zehong He
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

2.  Protocatechuic acid attenuates lipolysaccharide-induced acute lung injury.

Authors:  Miaomiao Wei; Xiao Chu; Lanxiang Jiang; Xiaofeng Yang; Qinren Cai; Chaochao Zheng; Xinxin Ci; Mingfeng Guan; Juxiang Liu; Xuming Deng
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

3.  A novel mechanism of nuclear factor-kappaB regulation by adenoviral protein 14.7K.

Authors:  Ruaidhrí J Carmody; Kimberly Maguschak; Youhai H Chen
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

4.  Interference with intraepithelial TNF-α signaling inhibits CD8(+) T-cell-mediated lung injury in influenza infection.

Authors:  Anon Srikiatkhachorn; Jyothi Chintapalli; Jun Liu; Mohammad Jamaluddin; Kevin S Harrod; Jeffrey A Whitsett; Richard I Enelow; Chilakamarti V Ramana
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

5.  Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.

Authors:  A E Tollefson; K Toth; K Doronin; M Kuppuswamy; O A Doronina; D L Lichtenstein; T W Hermiston; C A Smith; W S Wold
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury.

Authors:  Lucas Liaudet; Jon G Mabley; Pál Pacher; László Virág; Francisco G Soriano; Anita Marton; György Haskó; Edwin A Deitch; Csaba Szabó
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

7.  The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury.

Authors:  Jon G Mabley; Pal Pacher; Kanneganti G K Murthy; William Williams; Garry J Southan; Andrew L Salzman; Csaba Szabo
Journal:  Shock       Date:  2009-09       Impact factor: 3.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.